Navigation Links
Takeda Initiates Phase 3 Clinical Trial Program in the United States, Latin America, and Europe for Investigational Type 2 Diabetes Therapy TAK-875
Date:10/17/2011

OSAKA, Japan, Oct. 18, 2011 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") and its wholly-owned subsidiaries, Takeda Global Research & Development Center, Inc. ("TGRD U.S."), and Takeda Global Research & Development Centre (Europe), Ltd. ("TGRD Europe"), announced today the initiation of the Company's Phase 3 clinical trial program for TAK-875, an investigational therapy for type 2 diabetes. The program will be conducted across the United States (U.S.), Latin America, and Europe. TAK-875 is the first GPR40 agonist to reach late stage (Phase 3) clinical development.

Completed studies of TAK-875, discovered by Takeda, have suggested glucose-lowering effects in patients with type 2 diabetes by enhancing glucose-dependent insulin secretion.

"Takeda is committed to enhancing the clinical investigation of TAK-875 in order to accelerate the development of a potential new type 2 diabetes treatment option for patients and healthcare professionals," said Thomas Strack, M.D., vice president, clinical science, Takeda Global Research & Development Center, Inc., U.S. "An outcome of our robust focus on diabetes over many years, TAK-875 was discovered by Takeda based on our GPCR research and is the first GPR40 agonist to reach late stage (Phase 3) clinical development. TAK-875 is being developed globally, with Phase 3 trials already underway in Japan."

The first Phase 3 trial in the U.S./Europe program, a double-blind, randomized, 24-week safety and efficacy study, will enroll approximately 450 patients with type 2 diabetes who are not adequately controlled on diet and exercise, at approximately 140 sites in the U.S., Latin America, and Europe. The study's primary endpoint will be the change in HbA1c at week 24 while other endpoints will include the assessment of a clinically meaningful response based on reaching HbA1c targets, changes in fasting plasma glucose (FPG) and two-hour postprandial plasma glucose (PPG). Results are ex
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Takeda Completes Acquisition and Names New CEO of Nycomed
2. Amylin and Takeda Discontinue Development of Pramlintide/Metreleptin Combination Treatment for Obesity Following Commercial Reassessment of the Program
3. Takeda Resubmits New Drug Applications in the U.S. for Investigational Type 2 Diabetes Therapies Alogliptin and the Fixed-Dose Combination Alogliptin/Pioglitazone
4. Takeda Responds to U.S. Food and Drug Administration Update to Safety Review of ACTOS (pioglitazone HCl)
5. Takeda to Acquire Nycomed
6. Amylin and Takeda Voluntarily Suspend Clinical Activities in Obesity Trial
7. Intra-Cellular Therapies and Takeda Enter into Worldwide Collaboration to Develop and Commercialize Compounds for Schizophrenia
8. Handa Pharmaceuticals Announces Submission of Its First-to-File ANDA for Takedas DEXILANT®
9. Takeda Submits New Drug Application in the U.S. for Azilsartan Medoxomil Plus Chlorthalidone, an Investigational Fixed-Dose Combination for the Treatment of Hypertension
10. Takeda Enters Into Global Strategic Partnerships With Covance and Quintiles
11. Takeda Completes Settlements With All Defendants in U.S. Patent Litigation Involving ACTOS® (pioglitazone HCI), ACTOplus met® (pioglitazone HCl and metformin HCl) and duetact® (pioglitazone HCl and glimepiride)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... WASHINGTON and NEW YORK ... 2014 As the leading distributor of market ... a new research report by IQ4I Research and Consultancy ... To learn more about IQ4I Research visit: ... Active Pharmaceutical Ingredients Global Market – Forecast ...
(Date:11/26/2014)... 25, 2014 Reinforcing its commitment to enabling ... PHG AEX: PHIA) today announced 510(k) ... for its IQon Spectral CT , presenting an ... technology adds a new dimension to Computed Tomography (CT) ... characterize structures based on their material content within a ...
(Date:11/26/2014)... Pa. , Nov. 25, 2014  Unilife Corporation ... of injectable drug delivery systems, today announced that its ... to present at the Piper Jaffray 26th Annual Healthcare ... a.m. EST on Tuesday, December 2, 2014. ... Internet as a "live" listen only Webcast. To listen, ...
Breaking Medicine Technology:MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 3Philips receives FDA 510(k) clearance for IQon Spectral CT 2Philips receives FDA 510(k) clearance for IQon Spectral CT 3Unilife to Present at the Piper Jaffray 26th Annual Healthcare Conference on December 2nd 2
(Date:11/27/2014)... Vancouver, BC (PRWEB) November 27, 2014 ... http://www.idataresearch.com ), those companies looking to break into the ... in other medical specialties, other than the MIS field ... almost one-third of the U.S. surgical robotics market by ... nearing saturation,” explains Dr. Kamran Zamanian, CEO and President ...
(Date:11/27/2014)... PITTSBURGH, PA (PRWEB) November 27, 2014 ... suffer from an embarrassing fact of life, and she ... musty a few minutes later, I decided that there ... longer periods," she said. , Easy to use and ... maintains freshness in a woman’s private areas throughout the ...
(Date:11/27/2014)... Dennis Thompson HealthDay Reporter ... experimental Ebola vaccine appears to be safe and produces an ... virus, according to early clinical trial results reported by the ... phase I clinical trial for the vaccine paves the way ... Liberia and Sierra Leone as early as January, said Dr. ...
(Date:11/27/2014)... Now that Thanksgiving is finally here and ... Emassagechair.com has announced its eagerly awaited, once yearly ... Negotiating on behalf of their customers, and drawing on ... has generated significant buzz in the industry with the ... , Shoppers are excited for significant savings available on ...
(Date:11/27/2014)... 2014 “LAB.C” was featured on NewsWatch as ... and coolest technology products available to consumers. Mallory Sofastaii, a ... review and shared with viewers the company offers a ... devices. , Consumers love portability and functionality. A unique ... for the iPhone5 and 5S has a portable USB charger ...
Breaking Medicine News(10 mins):Health News:U.S. Robotic Surgery Market Set to Diversify and Grow: Intuitive Surgical’s ‘da Vinci’ Robot Revenues to Increasingly Rely On Procedures and Services 2Health News:Early Trial Promising for Ebola Vaccine 2Health News:Early Trial Promising for Ebola Vaccine 3Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 2Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 3Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 4Health News:Top Mobile Friendly Accessories were Featured on NewsWatch Television on October 30, 2014 2
... to restart production of missing protein , TUESDAY, Aug. ... muscle appears to jump-start the production of a crucial ... British researchers report. , The treatment so far is ... the debilitating and ultimately fatal disease, but scientists are ...
... , , , ... over $800,000 on prescription drugs through Iowa Drug Card since the launch ... free discount drug cards to Iowa residents, was launched in June, 2008. ... program. , , Former Hawkeye,s Head Football Coach ...
... TSX: COM, , , VANCOUVER, Aug. 25 ... ("Cardiome" or the "Company") announced today that its Board of ... to purchase for cancellation up to 6,470,588 of its common ... million. The offer will be conducted as a modified "Dutch ...
... , IRVINE, Calif., Aug. 25 CorVel Corporation ... Board of Directors has approved a 1,000,000 share expansion to its ... for repurchase over the life of the program to 14,150,000 shares. ... program in the fall of 1996. From the program,s inception through ...
... , CHARLES TOWN, W.Va., Aug. 25 ReBuilder ... treatments for the pain resulting from Peripheral Neuropathy and Peripheral ... and is now reporting profits for the first Quarter of ... ) , , "Our efforts to ...
... , , CENTER CITY, ... helps people reclaim their lives from addiction, has appointed William ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20061128/CGTU038LOGO ) , (Photo: ... to announce the appointment of William C. Moyers as Vice ...
Cached Medicine News:Health News:Experimental Treatment Could Fight Muscular Dystrophy 2Health News:Iowa Drug Card a Huge Success With Iowans 2Health News:Cardiome Pharma Corp. Announces Tender Offer To Purchase Up To US$27.5 Million Of Its Common Shares 2Health News:Cardiome Pharma Corp. Announces Tender Offer To Purchase Up To US$27.5 Million Of Its Common Shares 3Health News:Cardiome Pharma Corp. Announces Tender Offer To Purchase Up To US$27.5 Million Of Its Common Shares 4Health News:Cardiome Pharma Corp. Announces Tender Offer To Purchase Up To US$27.5 Million Of Its Common Shares 5Health News:Cardiome Pharma Corp. Announces Tender Offer To Purchase Up To US$27.5 Million Of Its Common Shares 6Health News:CorVel Announces Expansion to Share Buyback Program 2Health News:CorVel Announces Expansion to Share Buyback Program 3Health News:ReBuilder Medical Technologies, Inc. Announces First Quarter 2009 is Profitable 2Health News:William C. Moyers Appointed Vice President of Foundation Relations for Hazelden 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: